Fund provides exposure to one of the fastest-growing blockchain networks for real-world use cases and enterprise infrastructure. Â
Larger order for 2023 follows initial order for supply in 2022 COPENHAGEN, Denmark, August 3, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today...
U.S. approval follows successful pre-approval inspection of the facility by the U.S. FDAEU approval obtained after submission of application to EMA in June...
COPENHAGEN, Denmark, July 25, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission (EC) has extended the marketing...
Bavarian Nordic to supply an additional 1.5 million doses of IMVANEX® vaccine to an undisclosed European countryDeliveries starting in the fourth quarter...
A number of contracts of varying size have been signedDeliveries to start immediately aiming to ensure a rapid response to the current monkeypox...
Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccine, bringing deliveries in 2022 and 2023 to a total of nearly 7 million...
Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccineDoses will be manufactured using existing bulk vaccine from previous orders...
COPENHAGEN, Denmark, June 28, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Medicines Agency (EMA) has granted access to its...
COPENHAGEN, Denmark, June 28, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Medicines Agency (EMA) has granted access to its...